Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 10, 2026, 11:30 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 174 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Matched Unrelated Donor Hematopoietic Stem Cell Transplant Clear all
Completed Phase 1Phase 2 Interventional Results available

Autologous and Allogeneic Transplant for Relapsed Lymphoma

NCT00802113
View directory record Official record
Conditions
Non-Hodgkin's Lymphoma, Hodgkins Disease
Interventions
Fludarabine, Busulfan, Anti-Thymocyte Globulin
Drug
Lead sponsor
Columbia University
Other
Eligibility
Up to 55 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2014
U.S. locations
6
States / cities
Chicago, Illinois • Hackensack, New Jersey • New York, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 27, 2019 · Synced Oct 10, 2026, 11:30 PM EDT
Completed Phase 1 Interventional

Fludarabine Phosphate, Clofarabine, and Busulfan With Vorinostat in Treating Patients With Acute Leukemia in Remission or Relapse Undergoing Donor Stem Cell Transplant

NCT02083250
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia in Remission, Acute Myeloid Leukemia in Remission, Allogeneic Hematopoietic Stem Cell Transplantation Recipient, Myelodysplastic Syndrome, Previously Treated Myelodysplastic Syndrome, Recurrent Acute Lymphoblastic Leukemia, Recurrent Acute Myeloid Leukemia
Interventions
Allogeneic Bone Marrow Transplantation, Allogeneic Hematopoietic Stem Cell Transplantation, Anti-Thymocyte Globulin, Busulfan, Clofarabine, Fludarabine Phosphate, Peripheral Blood Stem Cell Transplantation, Pharmacological Study, Vorinostat
Procedure · Biological · Drug + 1 more
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Up to 60 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 6, 2022 · Synced Oct 10, 2026, 11:30 PM EDT
Completed Phase 1 Interventional Results available

Rasburicase in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer or Other Disease Undergoing Donor Stem Cell Transplant

NCT00513474
View directory record Official record
Conditions
Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
Interventions
busulfan, cyclophosphamide, cyclosporin-A, etoposide, methotrexate, rasburicase, sirolimus, tacrolimus, allogeneic hematopoietic stem cell transplantation, peripheral blood stem cell transplantation, total-body irradiation, fludarabine, allopurinol
Drug · Procedure · Radiation
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 25, 2017 · Synced Oct 10, 2026, 11:30 PM EDT
Completed Phase 2 Interventional Results available

Blood Stem Cell Transplantation for the Treatment of Older Patients With Acute Myelogenous Leukemia

NCT00623935
View directory record Official record
Conditions
Acute Myelogenous Leukemia
Interventions
Fludarabine, Busulfan, Total Body Irradiation, Stem Cell Transplant
Drug · Radiation · Procedure
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
55 Years to 70 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2015
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 8, 2016 · Synced Oct 10, 2026, 11:30 PM EDT
Completed No phase listed Observational

Cytomegalovirus (CMV) Viremia and Disease Occurrence in Pediatric Allogeneic Stem Cell Transplantation Recipients

NCT04478474
View directory record Official record
Conditions
Cytomegalovirus Infections
Interventions
Ganciclovir
Drug
Lead sponsor
New York Medical College
Other
Eligibility
Up to 26 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Valhalla, New York
Source: ClinicalTrials.gov public record
Updated Oct 26, 2023 · Synced Oct 10, 2026, 11:30 PM EDT
Completed Phase 2 Interventional Results available

Pilot and Feasibility Study of Reduced-Intensity Hematopoietic Stem Cell Transplant for MonoMAC

NCT00923364
View directory record Official record
Conditions
MDS, Immunodeficiency, GATA2
Interventions
Cyclophosphamide (CTX, Cytoxan), Fludarabine(Fludara,Berlex Laboratories), Total Body Irradiation (TBI), Allogeneic Hematopoietic Stem Cell (HSC), Equine Anti-Thymocyte Globulin
Drug · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
12 Years to 60 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2017
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 12, 2020 · Synced Oct 10, 2026, 11:30 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Sorafenib, Busulfan and Fludarabine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia Undergoing Donor Stem Cell Transplant

NCT03247088
View directory record Official record
Conditions
Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
Interventions
Allogeneic Hematopoietic Stem Cell Transplantation, Busulfan, Cyclophosphamide, Filgrastim, Fludarabine, Mycophenolate Mofetil, Sorafenib, Tacrolimus
Procedure · Drug · Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 70 Years
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 10, 2026 · Synced Oct 10, 2026, 11:30 PM EDT
Recruiting Phase 2 Interventional

Allogeneic HSCT With Low-Dose Post-Transplant Cyclophosphamide for GVHD Prevention

NCT06926595
View directory record Official record
Conditions
Graft-versus-Host Disease (GVHD), Hematologic Malignancies, Allogeneic Stem Cell Transplantation
Interventions
Cyclophosphamide (primary intervention for GVHD prophylaxis)
Drug
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 3, 2026 · Synced Oct 10, 2026, 11:30 PM EDT
Completed Phase 2 Interventional Results available

Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer

NCT00054327
View directory record Official record
Conditions
Leukemia, Lymphoma, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases
Interventions
busulfan, cyclophosphamide, cytarabine, radiation therapy, Etoposide, Stem Cell Transfusion
Drug · Radiation · Procedure
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
Up to 55 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2011
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 24, 2013 · Synced Oct 10, 2026, 11:30 PM EDT
Active, not recruiting Phase 2 Interventional

Alpha/Beta T and CD19+ Depleted Peripheral Stem Cells for Patients With Primary Immunodeficiencies

NCT02990819
View directory record Official record
Conditions
Immunodeficiencies, Immune Dysregulation Syndromes
Interventions
Apha/beta T and CD19+ cell depletion using CliniMACS device
Device
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
Up to 25 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 10, 2025 · Synced Oct 10, 2026, 11:30 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Allogeneic Hematopoietic Cell Transplantation for Patients With Busulfex-based Regimen

NCT00448357
View directory record Official record
Conditions
Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
Interventions
rabbit anti-thymocyte globulin (ATG), therapeutic allogeneic lymphocytes, busulfan, fludarabine phosphate, tacrolimus, allogeneic hematopoietic stem cell transplantation, peripheral blood stem cell transplantation, methotrexate
Biological · Drug · Procedure
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years to 55 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2015
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 17, 2017 · Synced Oct 10, 2026, 11:30 PM EDT
Terminated Early Phase 1 Interventional

A Multi-Institutional Pilot Study of Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Malignant Neuro-Epithelial and Other Solid Tumors

NCT02653196
View directory record Official record
Conditions
Neuroepithelial Tumor, Solid Tumor, Allogeneic Hematopoietic Stem Cell Transplantation
Interventions
Allogeneic hematopoietic stem cell transplant following thiotepa-based marrow ablative chemotherapy, Keratinocyte Growth Factor, Alemtuzumab, Thiotepa, Etoposide, Fludarabine, Melphalan, Tacrolimus, Cyclosporine A, Mycophenolate mofetil
Procedure · Drug
Lead sponsor
Montefiore Medical Center
Other
Eligibility
Up to 60 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Aug 17, 2017 · Synced Oct 10, 2026, 11:30 PM EDT
Completed Phase 1 Interventional

Hematopoietic Stem Cell Transplant for Sickle Cell Disease

NCT02065596
View directory record Official record
Conditions
Sickle Cell Disease, Sickle Cell Anemia, SCD
Interventions
Fludarabine, Hematopoietic Stem Cell Transplant (HSCT)
Drug · Procedure
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years to 65 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2023
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 29, 2024 · Synced Oct 10, 2026, 11:30 PM EDT
Not yet recruiting Phase 1Phase 2 Interventional

Phase 1b/2a Trial of Allogeneic HSCT From an HLA-partially Matched Related or Unrelated Donor After TCRab+ T-cell/CD19+ B-cell Depletion for Patients With Monogenic and/or Early-onset Medically Refractory Crohn Disease

NCT06986382
View directory record Official record
Conditions
Crohn Disease
Interventions
CliniMACS® TCR α/β Reagent Kit and CliniMACS® CD19 System, Prednisone/Methylprenisolone, Palifermin, ATG, Clofarabine, Melphalan, Total Body Irradiation, Rituximab
Device · Drug · Radiation
Lead sponsor
Stanford University
Other
Eligibility
2 Years to 30 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2040
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated May 23, 2025 · Synced Oct 10, 2026, 11:30 PM EDT
Completed Phase 2 Interventional Results available

Hematopoietic Cell Transplantation for Pediatric Patients With Hematologic Malignancies

NCT00795132
View directory record Official record
Conditions
Acute Leukaemia, Chronic Disease, Leukemia, Myelodysplasia, Lymphoma
Interventions
Busulfan, Anti-Thymocyte Globulin, Fludarabine, Cyclosporine, Mycophenolate mofetil
Drug
Lead sponsor
University of Utah
Other
Eligibility
Up to 21 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jul 30, 2013 · Synced Oct 10, 2026, 11:30 PM EDT
Completed Phase 3 Interventional Results available

Tacrolimus and Methotrexate With or Without Sirolimus in Preventing Graft-Versus-Host Disease in Young Patients Undergoing Donor Stem Cell Transplant for Acute Lymphoblastic Leukemia in Complete Remission

NCT00382109
View directory record Official record
Conditions
B-cell Childhood Acute Lymphoblastic Leukemia, Childhood Acute Lymphoblastic Leukemia in Remission, Graft Versus Host Disease, L1 Childhood Acute Lymphoblastic Leukemia, L2 Childhood Acute Lymphoblastic Leukemia, T-cell Childhood Acute Lymphoblastic Leukemia
Interventions
thiotepa, cyclophosphamide, tacrolimus, methotrexate, sirolimus, total body irradiation
Drug · Radiation
Lead sponsor
Children's Oncology Group
Network
Eligibility
1 Year to 21 Years
Enrollment
146 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2017
U.S. locations
44
States / cities
Phoenix, Arizona • Duarte, California • Oakland, California + 40 more
Source: ClinicalTrials.gov public record
Updated Aug 7, 2019 · Synced Oct 10, 2026, 11:30 PM EDT
Withdrawn Phase 2 Interventional

Busulfan and Fludarabine Before Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer

NCT00301912
View directory record Official record
Conditions
Anemia, Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases
Interventions
filgrastim, busulfan, fludarabine phosphate, methotrexate, tacrolimus, allogeneic bone marrow transplantation, allogeneic hematopoietic stem cell transplantation, peripheral blood stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
University of California, San Francisco
Other
Eligibility
16 Years to 60 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Oct 2, 2012 · Synced Oct 10, 2026, 11:30 PM EDT
Withdrawn Phase 1 Interventional

²¹¹At-OKT10-B10 and Fludarabine Alone or in Combination With Cyclophosphamide and Low-Dose TBI Before Donor Stem Cell Transplant for the Treatment of Newly Diagnosed, Recurrent, or Refractory High-Risk Multiple Myeloma

NCT04579523
View directory record Official record
Conditions
Multiple Myeloma, Recurrent Multiple Myeloma, Refractory Multiple Myeloma
Interventions
Allogeneic Hematopoietic Stem Cell Transplantation, Astatine At 211 Anti-CD38 Monoclonal Antibody OKT10-B10, Cyclophosphamide, Fludarabine Phosphate, Total-Body Irradiation, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, X-Ray Imaging
Procedure · Biological · Drug + 1 more
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2029
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Oct 10, 2026, 11:30 PM EDT
Withdrawn Phase 1Phase 2 Interventional

Reduced Intensity Conditioning Allogeneic Hematopoietic Stem Cell Transplant (HSCT) For Lymphoma

NCT02724904
View directory record Official record
Conditions
Lymphoma
Interventions
Allogeneic stem cell transplantation, Fludarabine, Thiotepa, Methotrexate
Procedure · Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 22, 2017 · Synced Oct 10, 2026, 11:30 PM EDT
Completed Phase 2 Interventional Results available

Early Administration of ATG Followed by Cyclophosphamide, Busulfan and Fludarabine Before a Donor Stem Cell Transplant in Patients With Hematological Cancer

NCT00787761
View directory record Official record
Conditions
Myeloproliferative Disorders, Kidney Cancer, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases
Interventions
anti-thymocyte globulin, busulfan, cyclophosphamide, fludarabine phosphate, methotrexate, tacrolimus, nonmyeloablative allogeneic HSCT
Biological · Drug · Procedure
Lead sponsor
Northside Hospital, Inc.
Other
Eligibility
Up to 75 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Oct 1, 2012 · Synced Oct 10, 2026, 11:30 PM EDT
Recruiting Phase 1 Interventional

Stem Cell Transplant From Donors After Alpha Beta Cell Depletion in Children and Adults With T-allo10 Cells Addback

NCT04640987
View directory record Official record
Conditions
Hematologic Diseases
Interventions
Allogeneic Stem Cell Transplant, CliniMACS Prodigy System, T-allo10 cells addback
Biological · Device · Drug
Lead sponsor
Porteus, Matthew, MD
Other
Eligibility
1 Month to 45 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Jan 8, 2026 · Synced Oct 10, 2026, 11:30 PM EDT
Completed Phase 2 Interventional

Phase II Study Evaluating Busulfan and Fludarabine as Preparative Therapy in Adults With Hematopoietic Disorders Undergoing MUD SCT

NCT00516152
View directory record Official record
Conditions
Chronic Myeloid Leukemia, Acute Myelogenous Leukemia, Myelodysplasia, Acute Lymphocytic Leukemia, Severe Aplastic Anemia, Non-Hodgkin's Lymphoma, Lymphoproliferative Disease, Multiple Myeloma, Advanced Myeloproliferative Disease
Interventions
Busulfan/Fludarabine phosphate/Tacrolimus/Methotrexate/G-CSF
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
15 Years to 61 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2007
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jan 26, 2009 · Synced Oct 10, 2026, 11:30 PM EDT
Terminated Phase 2 Interventional Results available

Iodine I 131 Monoclonal Antibody BC8, Fludarabine Phosphate, Total Body Irradiation, and Donor Stem Cell Transplant Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients With Advanced Acute Myeloid Leukemia or Myelodysplastic Syndrome

NCT00119366
View directory record Official record
Conditions
Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Childhood Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, Previously Treated Myelodysplastic Syndromes, Recurrent Adult Acute Myeloid Leukemia, Recurrent Childhood Acute Myeloid Leukemia, Refractory Anemia With Excess Blasts, Refractory Anemia With Excess Blasts in Transformation, Refractory Anemia With Ringed Sideroblasts, Refractory Cytopenia With Multilineage Dysplasia, Secondary Acute Myeloid Leukemia, Secondary Myelodysplastic Syndromes
Interventions
iodine I 131 monoclonal antibody BC8, fludarabine phosphate, total-body irradiation, allogeneic hematopoietic stem cell transplantation, peripheral blood stem cell transplantation, cyclosporine, mycophenolate mofetil, laboratory biomarker analysis
Radiation · Drug · Procedure + 1 more
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
16 Years to 50 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2019
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Dec 12, 2022 · Synced Oct 10, 2026, 11:30 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Bilateral Orthotopic Lung Transplant - Bone Marrow Transplant

NCT03330795
View directory record Official record
Conditions
Primary Immunodeficiency, PID
Interventions
CD3/CD19 neg allogeneic BMT
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
10 Years to 45 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 22, 2025 · Synced Oct 10, 2026, 11:30 PM EDT